

Severe Occupational Asthma: Insights From a Multicenter European Cohort



Olivier Vandenplas, MD, PhD^a, Julien Godet, PharmD, PhD^b, Laura Hurdubaea, MD^c, Catherine Riffart, MSc^a, Hille Suojalehto, MD, PhD^d, Jolanta Walusiak-Skorupa, MD^e, Xavier Munoz, MD^f, Joaquin Sastre, MD^g, Pavlina Klusackova, MD^h, Vicky Moore, PhDⁱ, Rolf Merget, MD^j, Donatella Talini, MD^k, Jorunn Kirkeleit, MD^l, Paola Mason, MD^m, Ilenia Folletti, MDⁿ, Paul Cullinan, MD^o, Gianna Moscato, MD^p, Santiago Quirce, MD^q, Jennifer Hoyle, MD^r, David Sherson, MD^s, Paula Kauppi, MD^t, Alexandra Preisser, MD^u, Nicolas Meyer, MD, PhD^b, and Frédéric de Blay, MD^c; on behalf of the European network for the PHenotyping of OCCupational ASthma (E-PHOCAS) investigators Yvoir, Belgium; Strasbourg, France; Helsinki, Finland; Lodz, Poland; Barcelona and Madrid, Spain; Prague, Czech Republic; Birmingham, London, and Manchester, United Kingdom; Bochum and Hamburg, Germany; Pisa, Padova, Perugia, and Pavia, Italy; Bergen, Norway; and Odense, Denmark

What is already known about this topic? There is only scarce information on the burden and determinants of severe sensitizer-induced occupational asthma (OA).

What does this article add to our knowledge? This cohort study indicates that a substantial fraction of subjects with OA (16.2%; 95% CI, 14.0%-18.7%) experience severe asthma. The findings highlight exposure-related and individual risk factors for severe OA.

How does this study impact current management guidelines? The findings of this cohort study may assist clinicians and health policymakers identify potentially modifiable risk factors for severe OA that should be targeted in strategies aimed at minimizing the health and socioeconomic impacts of the disease.

^aDepartment of Chest Medicine, Centre Hospitalier Universitaire UCL Namur, Université Catholique de Louvain, Yvoir, Belgium

^bGroupe Méthode Recherche Clinique, Pôle de Santé Publique, Strasbourg University, Strasbourg, France

^cDivision of Asthma and Allergy, Department of Chest Diseases, University Hospital of Strasbourg and Fédération de Médecine translationnelle, Strasbourg University, Strasbourg, France

^dOccupational Medicine, Finnish Institute of Occupational Health, Helsinki, Finland

^eDepartment of Occupational Diseases and Environmental Health, Nofer Institute of Occupational Medicine, Lodz, Poland

^fServei Pneumologia, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona and CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain

^gDepartment of Allergy, Fundación Jiménez Díaz and CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain

^hDepartment of Occupational Medicine, 1st Faculty of Medicine, Charles University, Prague, Czech Republic

ⁱOccupational Lung Disease Unit, Birmingham Heartlands Hospital, Birmingham, United Kingdom

^jInstitute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Ruhr University, Bochum, Germany

^kCardio-Thoracic and Vascular Department, University of Pisa, Pisa, Italy

^lDepartment of Occupational Medicine, Haukeland University Hospital, Bergen, Norway

^mUnit of Occupational Medicine and Public Health, University of Padova, Padova, Italy

ⁿDepartment of Medicine, Section of Occupational Medicine, Respiratory Diseases and Occupational and Environmental Toxicology, University of Perugia, Perugia, Italy

^oDepartment of Occupational and Environmental Medicine, Royal Brompton Hospital and Imperial College (NHLI), Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom

^pDepartment of Public Health, Experimental and Forensic Medicine, University of Pavia, and Allergy and Immunology Unit, Istituti Clinici Scientifici Maugeri, IRCCS, Pavia, Italy

^qDepartment of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ) and CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain

^rDepartment of Respiratory Medicine, North Manchester General Hospital, Manchester, United Kingdom

^sDepartment of Pulmonary Medicine and Occupational Medicine, Odense University Hospital, Odense, Denmark

^tDepartment of Allergy, Skin and Allergy Hospital, Helsinki University Central Hospital, Helsinki, Finland

^uInstitute for Occupational and Maritime Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

This work was funded in part by a Task Force of the European Academy of Allergy and Clinical Immunology. O.V. and C.R. were supported by a grant from the *Fondation Mont-Godinne*. J.S. was supported in part by CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Ministry of Economy and Competitiveness, Spain.

Conflicts of interest: The authors declare that they have no relevant conflicts of interest.

Received for publication December 18, 2018; revised February 13, 2019; accepted for publication March 8, 2019.

Available online March 23, 2019.

Corresponding author: Olivier Vandenplas, MD, PhD, Department of Chest Medicine, Centre Hospitalier Universitaire UCL Namur, Université Catholique de Louvain, 1 Avenue G. Therasse, B-5530 Yvoir, Belgium. E-mail: olivier.vandenplas@uclouvain.be.

2213-2198

© 2019 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology

<https://doi.org/10.1016/j.jaip.2019.03.017>

Abbreviations used

GINA- Global Initiative for Asthma

HMW- High-molecular-weight

LMW- Low-molecular-weight

OA- occupational asthma

OR- Odds ratio

SA- Severe asthma

SIC- Specific inhalation challenge

BACKGROUND: Although sensitizer-induced occupational asthma (OA) accounts for an appreciable fraction of adult asthma, the severity of OA has received little attention.

OBJECTIVE: The aim of this study was to characterize the burden and determinants of severe OA in a large multicenter cohort of subjects with OA.

METHODS: This retrospective study included 997 subjects with OA ascertained by a positive specific inhalation challenge completed in 20 tertiary centers in 11 European countries during the period 2006 to 2015. Severe asthma was defined by a high level of treatment and any 1 of the following criteria: (1) daily need for a reliever medication, (2) 2 or more severe exacerbations in the previous year, or (3) airflow obstruction.

RESULTS: Overall, 162 (16.2%; 95% CI, 14.0%-18.7%) subjects were classified as having severe OA. Multivariable logistic regression analysis revealed that severe OA was associated with persistent (vs reduced) exposure to the causal agent at work (odds ratio [OR], 2.78; 95% CI, 1.50-5.60); a longer duration of the disease (OR, 1.04; 95% CI, 1.00-1.07); a low level of education (OR, 2.69; 95% CI, 1.73-4.18); childhood asthma (OR, 2.92; 95% CI, 1.13-7.36); and sputum production (OR, 2.86; 95% CI, 1.87-4.38). In subjects removed from exposure, severe OA was associated only with sputum production (OR, 3.68; 95% CI, 1.87-7.40); a low education level (OR, 3.41; 95% CI, 1.72-6.80); and obesity (OR, 1.98; 95% CI, 0.97-3.97).
CONCLUSIONS: This study indicates that a substantial proportion of subjects with OA experience severe asthma and identifies potentially modifiable risk factors for severe OA that should be targeted to reduce the adverse impacts of the disease. © 2019 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology (J Allergy Clin Immunol Pract 2019;7:2309-18)

Key words: Occupational asthma; Severe asthma; Asthma exacerbations; Asthma control; Airflow obstruction

INTRODUCTION

Severe asthma (SA) imposes a substantial public health burden because the condition has a major impact on patients' quality of life and accounts for a disproportionately large portion of health care costs associated with asthma.^{1,2} Clinical practice guidelines advocate the identification and remediation of exposures contributing to asthma severity as a key step in disease management.^{1,3} Among potentially modifiable exposures, the workplace environment is likely to hold a notable position because workplace exposures to high-molecular-weight (HMW) and low-molecular-weight (LMW) asthmagenic agents have been associated with an increased risk of poor asthma control and severe exacerbations.^{4,5}

Sensitizer-induced occupational asthma (OA), a distinguishable phenotype of work-related asthma, is characterized by the *de novo* inception of asthma or the recurrence of previously quiescent asthma induced by immunologically mediated sensitization to a specific agent at the workplace.^{6,7} Enhancing our knowledge of the burden and determinants of severe OA may be relevant from both clinical and health-economic perspectives. Complete avoidance of exposure to the causal agent is the recommended treatment option for OA but is associated with a higher socioeconomic impact as compared with reduction of exposure.^{6,8-11} The severity of asthma at the time of diagnosis has been consistently identified as a risk factor for a worse outcome after removal from exposure.^{6,8,12} However, the determinants of OA severity have so far received little attention.^{13,14}

The aim of this study was to estimate the burden of severe OA and to identify its determinant factors in a large multicenter cohort of subjects with OA confirmed by specific inhalation challenge (SIC).

METHODS

Study design and population

This retrospective, cross-sectional, observational study was conducted in an international, multicenter cohort of subjects with OA recruited from 20 tertiary centers in 11 European countries. Eligible subjects were those with a diagnosis of OA ascertained by a positive SIC completed between January 2006 and December 2015. From the 1180 eligible subjects with a positive SIC, 183 subjects with missing data pertaining to the variables used for assessing asthma severity and control were excluded from this analysis (Figure 1; see Appendix E1 in this article's Online Repository at www.jaci-inpractice.org).

Ethics

Each participating center was requested to obtain approval from its local Institutional Review Board for this analysis of retrospective anonymized data. The central database at the Strasbourg University was approved by the "Comité Consultatif sur le Traitement de l'Information en Matière de Recherche dans le Domaine de la Santé" and the "Commission Nationale de l'Informatique et des Libertés."

Demographic and clinical characteristics

Information on demographic, clinical, occupational, and physiological characteristics of the subjects at the time of the diagnostic evaluation was entered in a standardized database in each participating center (see Appendix E1). The requested data were retrospectively retrieved from medical charts in 10 centers, whereas they had been longitudinally entered in existing local databases in the remaining centers.

Briefly, the database gathered information on the following items: (1) causal agent and job; (2) demographic characteristics; (3) clinical features; (4) nature and timing of exposure to the causal agent and work-related respiratory symptoms; (5) coexisting disorders (ie, physician-based diagnosis of work-related rhinitis, conjunctivitis, daily sputum production, dysphonia, contact urticaria and/or dermatitis, and sinusitis). Investigators were asked to provide detailed asthma medications used: (1) during the last month of exposure at work and (2) during the last month before the SIC procedure for those subjects who were no longer exposed to the causal agent at that time. The frequency of short-acting β_2 -agonist use was categorized as "never," "once a week or less," "two or three times a week," "once or two times per day," or "three




FIGURE 1. Flowchart of the study population. *NSBH*, Nonspecific bronchial hyperresponsiveness (see [Appendix E1](#)).

or more times a day” similar to the Asthma Control Test.¹⁵ Data on the number of severe exacerbations during (1) the last 12 months at work and (2) during the last 12 months before the SIC procedure for those subjects who had been removed from exposure were also collected. The level of exposure to the causal agent during the last month at work was graded by the investigators as being “unchanged/persistent” (ie, similar to the conditions of exposure that prevailed at the time of asthma onset) or “reduced.” Data on biomarkers of airway inflammation were not included in this analysis because this information was available for a limited fraction of the subjects.

Lung function assessments

The database collected the baseline prebronchodilator forced vital capacity and FEV₁ values measured at the time of the SIC procedure before challenge exposure to the causal agent. The level of

nonspecific bronchial hyperresponsiveness at baseline and 24 hours after challenge exposure was recorded and expressed as the concentration or dose of the pharmacological agent inducing a 15% or 20% fall in FEV₁ according to the bronchoprovocation method used in each center (see [Appendix E2](#) and [Table E1](#) in this article’s Online Repository at www.jaci-inpractice.org).

SICs were performed according to international recommendations pertaining to the performance of a control (placebo) challenge and the duration of the functional monitoring after the end of the active challenge exposure.^{16,17} For each SIC, the database requested information on the method used for delivering the suspected occupational agent either through a “realistic” approach mimicking the workplace exposure or the inhalation of “allergen extract.” More detailed information on the methodology of SICs is available in [Appendix E3](#) in this article’s Online Repository at www.jaci-inpractice.org.

Asthma outcomes

Asthma treatment. The intensity of asthma treatment was graded *a posteriori* according to the treatment steps proposed by the Global Initiative for Asthma (GINA).³ High-level treatment was defined as treatment step 4 or 5 (ie, use of a high dose of inhaled corticosteroid and a second controller or systemic corticosteroid use >50% of the previous year).

Asthma control. The need for an inhaled short-acting β_2 -agonist for symptom relief was used as a proxy for the level of symptom control because most centers did not use validated instruments for the assessment of asthma control. For the purpose of this study, “poor symptom control” was therefore defined by the need for a short-acting β_2 -agonist once or more a day as proposed in the American Thoracic Society recommendations issued in 2000.¹⁸

Exacerbations. Severe exacerbations were defined as those requiring oral corticosteroids for at least 3 consecutive days or emergency room visit or hospitalization.^{19,20}

Airflow obstruction. Baseline airflow obstruction was defined by an FEV₁ less than 80% predicted value together with an FEV₁/forced vital capacity ratio of less than 0.70.

Severe asthma. The definition of SA was adapted from the European Respiratory Society/American Thoracic Society criteria^{1,3} and required a high-level treatment (ie, GINA treatment step 4-5) together with any 1 of the following criteria indicating uncontrolled asthma: (1) “poor symptom control”; (2) 2 or more severe exacerbations in the previous year; or (3) airflow obstruction.

Data analysis

Continuous measures were summarized by medians and interquartile ranges and categorical variables by their frequencies and proportions. Comparison between subjects with and without severe OA was made using the Fisher exact test or the chi-square test for categorical variables and the Wilcoxon rank-sum test for numerical variables.

Multivariable logistic regression analysis was carried out using a binomial generalized linear model, and the best parsimonious models were selected using a stepwise procedure based on Akaike information criterion to identify the clinical and physiological characteristics that were associated with severe OA. The potential explanatory variables incorporated into these regressions are detailed in [Appendix E4](#) in this article's Online Repository at www.jaci-inpractice.org. Additional multivariable logistic regression analyses were conducted to investigate the variables associated with each of the domains used to define SA: high-intensity treatment; poor symptom control; 2 or more severe exacerbations during the last 12 months at work; and airflow obstruction measured at the time of the SIC procedure (see [Appendix E4](#)).

In subjects who were removed from exposure at the time of the diagnostic evaluation (n = 467), the components of asthma severity at this time point were compared with those recorded when the subjects were still exposed at work. A multivariable logistic regression was also used to identify the clinical and physiological characteristics that were associated with SA at the time of the SIC. Missing values were not imputed, and subjects with missing data were not incorporated in multivariable analyses. Statistical analysis was performed using the R software version 3.4.1 (R Core Team, Vienna, Austria). A *P* value of less than .05 was considered significant.

RESULTS

Population

The population included 997 patients with OA ascertained by a positive SIC result (see [Appendix E1](#) and [Figure 1](#)). The demographic, clinical, and functional characteristics of the cohort are presented in [Tables I](#) and [II](#). The occupational agents that induced a positive SIC response are summarized in [Table E2](#) (available in this article's Online Repository at www.jaci-inpractice.org).

Severe OA while at work

The prevalence rates of high-level treatment, poor symptom control, 2 or more SA exacerbations during the last 12 months of exposure at work, and airflow obstruction were 30.3%, 30.2%, 8.7%, and 11.9%, respectively ([Tables I](#) and [II](#)). Overall, 162 (16.2%; 95% CI, 14.0-18.7) subjects were categorized as having severe OA.

Multivariable logistic regression analysis revealed that severe OA while at work was associated with “unchanged/persistent” (vs reduced) exposure to the causal agent at work (odds ratio [OR], 2.78; 95% CI, 1.50-5.60; *P* = .002) and a longer duration of work-related symptoms before SIC (OR, 1.04; 95% CI, 1.00-1.07, for every 12-month period of symptomatic exposure; *P* = .036) ([Table III](#)). There were also significant and independent associations between severe OA and a low level of education (ie, ≤6 years of school attendance) (OR, 2.69; 95% CI, 1.73-4.18; *P* < .001); a history of childhood asthma (ie, ≤12 years) (OR, 2.92; 95% CI, 1.13-7.36; *P* = .024); daily sputum production (OR, 2.86; 95% CI, 1.87-4.38; *P* < .001); and dysphonia at work (OR, 1.81; 95% CI, 1.00-3.18; *P* = .043). Subjects with severe OA were 2.5 times more likely (OR, 2.50; 95% CI, 1.16-7.08; *P* = .040) to have been investigated in centers with a “high SIC activity” (ie, >4 positive SICs per year).

The multivariable logistic regression models for each dimension of severe OA while exposed at work (ie, high-intensity treatment; poor symptom control; ≥2 severe exacerbations during the last 12 months at work; and airflow obstruction) are summarized in [Table IV](#).

Asthma severity in subjects removed from exposure

At the time of the SIC procedure, 467 (46.8%) subjects had already been removed from exposure to the causal agent for a median duration of 7.0 (3.0-13.0) months. The rates of poor symptom control and exacerbations were significantly reduced at the time of the SIC, whereas the intensity of treatment remained unchanged ([Table V](#)). Overall, the proportion of subjects with SA was 18.0% when the subjects were exposed at work and decreased to 11.1% (*P* = .004) when the subjects were removed from exposure at the time of SIC. In these subjects, a multivariable analysis showed that SA after removal from exposure was associated only with daily sputum production (OR, 3.68; 95% CI, 1.87-7.40; *P* < .001); a low level of education (OR, 3.41; 95% CI, 1.72-6.80; *P* < .001); and a body mass index of greater than or equal to 30 kg/m² (OR, 1.98; 95% CI, 0.97-3.97; *P* = .056).

DISCUSSION

Prevalence of severe OA

This cohort study indicates that a substantial fraction of subjects with OA (16.2%; 95% CI, 14.0%-18.7%) experience SA according to the multidimensional European Respiratory Society/

TABLE I. Demographic and clinical characteristics of the subjects

Characteristic	Missing values	All subjects (n = 997)	Subjects with SA* (n = 162)	Subjects with non-SA (n = 835)	P value
Age (y)†	0	42 (33-51)	44 (35-51)	42 (33-51)	0.190
Sex (male)	0	586 (58.8)	105 (64.8)	481 (57.6)	0.100
Body mass index					
kg/m ² ‡	15	27 (24-30)	27 (24-31)	27 (24-30)	0.130
≥30 kg/m ²	15	246 (25.1)	50 (30.9)	196 (23.9)	0.070
Smoking habits	21				0.570
Current smoker		195 (20.0)	36 (22.2)	159 (19.5)	
Ex-smoker		271 (27.8)	47 (29.0)	224 (27.5)	
Never-smoker		510 (52.2)	79 (48.8)	431 (53.0)	
Level of education	144				<0.001
Primary (≤6 y)		217 (25.4)	58 (45.7)	159 (21.9)	
Secondary (7-12 y)		562 (65.9)	62 (48.8)	500 (68.9)	
Postsecondary (>12 y)		74 (8.7)	7 (5.5)	67 (9.2)	
Ethnicity, nonwhite	3	60 (6.0)	18 (11.2)	42 (5.0)	0.006
Atopy‡	29	500 (51.6)	79 (51.6)	421 (51.7)	1.000
Age of asthma onset (y)	19				<0.001
<12		46 (4.7)	19 (11.8)	27 (3.3)	
12-18		15 (1.5)	3 (1.9)	12 (1.5)	
>18		917 (93.8)	139 (86.3)	778 (95.2)	
Type of causal agent, HMW	0	493 (49.4)	72 (44.4)	422 (50.5)	0.250
Duration of exposure before asthma onset (mo)†	16	84 (36-180)	76 (29-210)	84 (36-180)	0.800
Duration of symptomatic exposure (mo)†	12	30 (12-67)	36 (16-74)	28 (12-60)	0.020
Interval since last work exposure and SIC (mo)†	1	1.0 (0.1-8.0)	1.0 (0.1-8.8)	1.0 (0.1-7.8)	0.360
Exposure last month at work, unchanged/persistent§	0	762 (76.4)	138 (85.2)	624 (74.7)	0.003
Coexisting conditions					
Daily sputum production	16	287 (29.3)	80 (51.0)	207 (25.1)	<0.001
Work-related rhinitis	2	711 (71.5)	118 (72.8)	593 (71.2)	0.700
Work-related conjunctivitis	14	390 (39.7)	64 (39.8)	326 (39.7)	1.000
Chronic rhinosinusitis	8	117 (11.8)	25 (15.5)	92 (11.1)	0.140
Dysphonia at work	40	130 (13.6)	32 (20.5)	98 (12.2)	0.010
GINA treatment step while at work	0				<0.001
Treatment step 0		149 (14.9)	0	149 (17.8)	
Treatment step 1		143 (14.3)	0	143 (17.1)	
Treatment step 2		57 (5.7)	0	57 (6.8)	
Treatment step 3		346 (34.7)	0	346 (41.4)	
Treatment step 4		293 (29.4)	155 (95.7)	138 (16.5)	
Treatment step 5		9 (0.9)	7 (4.3)	2 (0.2)	
Inhaled short-acting β ₂ -agonist use while at work	0	732 (73.5)	153 (94.4)	579 (69.4)	<0.001
Never		265 (26.6)	9 (5.6)	256 (30.7)	
Once or less per week		195 (19.6)	5 (3.1)	190 (22.8)	
2 or more times a week		236 (23.7)	17 (10.5)	219 (26.2)	
≥1 times a day		301 (30.2)	131 (80.9)	170 (20.4)	
≥1 asthma exacerbation (last 12 mo at work)	0	232 (23.3)	77 (47.5)	155 (18.6)	<0.001
≥2 asthma exacerbations (last 12 mo at work)	0	87 (8.7)	40 (24.7)	47 (5.6)	<0.001
Work-related contact dermatitis	2	153 (15.4)	26 (16.1)	127 (15.2)	0.810

ICS, Inhaled corticosteroid.

Data are presented as n and % of available data unless otherwise specified. Values in boldface are statistically significant.

*Definition of SA adapted from the European Respiratory Society/American Thoracic Society criteria.¹

†Median value with interquartile range within parentheses.

‡Atopy defined by the presence of a positive skin prick test result to at least 1 common allergen.

§The level of exposure to the causal agent at work was qualitatively categorized by the investigators as “unchanged/persistent” or “reduced” compared with the conditions of exposure at the time of disease onset.

||The need for a short-acting β₂-agonist once or more a day was used as a proxy for “poor symptom control.”

TABLE II. Functional characteristics of the subjects

Characteristic	All subjects (n = 997)	Subjects with SA (n = 162)	Subjects with non-SA (n = 835)	P value
Baseline spirometry	(n = 997)	(n = 162)	(n = 835)	
FVC, % pred*	99 (89-109)	94 (84-105)	100 (91-110)	<.001
FEV ₁ , % pred*	91 (81-100)	80 (71-93)	92 (83-101)	<.001
FEV ₁ <80%	209 (21.0)	82 (50.6)	127 (15.2)	<.001
FEV ₁ /FVC*	77 (71-82)	70 (63-78)	77 (72-82)	<.001
FEV ₁ /FVC <70%	219 (22.0)	77 (47.5)	142 (17.0)	<.001
Airflow obstruction†	119 (11.9)	65 (40.1)	54 (6.5)	<.001
Baseline level of NSBH at the time of SIC‡	(n = 915)	(n = 153)	(n = 762)	.004
Absent	259 (28.3)	28 (18.3)	231 (30.3)	
Mild	403 (44.0)	71 (46.4)	332 (43.6)	
Moderate-to-severe	253 (27.6)	54 (35.3)	199 (26.1)	
Pattern of bronchial response to SIC	(n = 914)	(n = 155)	(n = 759)	
Isolated early reaction	349 (36.0)	55 (34.6)	294 (36.3)	.720
Isolated late reaction	226 (22.9)	33 (20.5)	193 (23.4)	.470
Dual reaction	339 (35.0)	67 (41.9)	272 (33.6)	.050

FVC, Forced vital capacity; NSBH, nonspecific bronchial hyperresponsiveness.

Data are presented as n (% of available data) unless otherwise specified. Values in boldface are statistically significant.

*Median value with interquartile range within parentheses.

†Airflow obstruction defined by an FEV₁ <80% predicted value and an FEV₁/FVC ratio of <0.70.

‡See Table E1 for the threshold values used for grading the level of NSBH.

TABLE III. Multivariable model for severe OA while at work

Independent variables	SA*	
	OR (95% CI)	P value
Exposure-related factors		
LMW causal agent, vs HMW		
Duration of symptomatic exposure, per 12-mo period	1.037 (1.002-1.073)	.036
“Unchanged/persistent” exposure at work, vs reduced†	2.78 (1.50-5.60)	.002
Sociodemographic factors		
Age >42 y		
Nonwhite ethnicity, vs white		
Low level of education, ≤6 y	2.69 (1.73-4.18)	<.001
Clinical features		
Childhood asthma, ≤12 y	2.92 (1.13-7.36)	.024
Daily sputum production, yes vs no	2.86 (1.86-4.38)	<.001
Chronic sinusitis, yes vs no		
Dysphonia at work, yes vs no	1.809 (1.002-3.179)	.043
Center-related characteristics		
“High-activity” center (ie, >4 positive SICs/y), yes vs no‡	2.50 (1.16-7.08)	.040

IQR, Interquartile range.

A total of 784 subjects were included in the multivariable model. An empty cell means that the independent variable was not retained in the final multivariable model and the corresponding OR was not available. Values in boldface are statistically significant.

*Definition of SA adapted from the European Respiratory Society/American Thoracic Society criteria.¹

†The level of exposure to the causal agent at work was qualitatively categorized by the investigators as “unchanged/persistent” or “reduced” compared with the conditions of exposure at the time of disease onset.

‡The level of activity of the centers was categorized as “high” and “low” on the basis of the median number of positive SICs reported annually (4.1; IQR, 2.5-7.5).

American Thoracic Society consensus definition of the disease.¹ This estimate is higher than those found in the general adult asthma population in 2 studies that applied the same definition of SA: 4.5% (95% CI, 3.9%-5.1%)²¹ and 6.3%.²² The prevalence of SA in the general adult asthma population remains, however, largely uncertain because available estimates have ranged from 2.3% to 36.2% in studies that used different definitions of SA in various population and clinic-based samples of adult patients with

asthma.²¹⁻²⁶ The findings in our OA cohort further support the data reported by Lemièrre et al^{27,28} who demonstrated that OA is associated with a higher risk of SA exacerbations requiring emergency room visit or hospitalization and a greater use of health care resources than non-work-related asthma. Nevertheless, further studies comparing OA with asthma unrelated to work are needed to confirm the challenging hypothesis that “asthma may be more severe if it is work-related.”²⁹

TABLE IV. Multivariable models for the factors that determine the domains of asthma severity and control while at work

Independent variables	High-level treatment*		Poor symptom control†		SA exacerbations‡		Airflow obstruction§	
	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)	P value
Exposure-related factors								
LMW	1.46 (1.03-2.06)	.032			1.83 (1.03-3.31)	.041		
Duration of symptomatic exposure	1.03 (1.00-1.06)	.038					1.05 (1.02-1.08)	.003
Level of exposure, unchanged/persistent¶	1.79 (1.16-2.81)	.009						
Sociodemographic factors								
Age >42 y							2.35 (1.50-3.73)	<.001
Nonwhite ethnicity			2.30 (1.93-4.92)	.029	2.61 (0.98-6.45)	.044		
Low level of education, ≤6 y	1.40 (0.95-2.05)	.086	2.43 (1.68-3.53)	<.001				
Clinical features								
Childhood asthma, ≤12 y			4.07 (1.70-10.18)	.002			2.26 (0.94-4.96)	.052
Daily sputum production (yes vs no)	1.93 (1.35-2.77)	<.001	1.62 (1.13-2.32)	.008	1.98 (1.11-3.50)	.019	1.62 (1.05-2.49)	.028
Chronic sinusitis	1.99 (1.21-3.24)	.006						
Dysphonia at work	1.96 (1.20-3.16)	.006						
Asthma-related factors								
High-level treatment*	NA		1.61 (1.11-2.31)	.011	2.48 (1.41-4.37)	.002		
Poor symptom control†	1.76 (1.20-2.57)	.004	NA		4.46 (2.56-7.88)	<.001	1.58 (0.97-2.54)	.060
Exacerbation, ≥2 last 12 mo‡	2.63 (1.50-4.61)	<.001	4.02 (2.32-7.08)	<.001	NA		2.31 (1.10-4.62)	.021
Center-related characteristics								
“High-activity” center (ie, >4 positive SICs/y)¶¶	1.76 (1.02-3.30)	.054	5.21 (2.40-14.92)	<.001				

IQR, Interquartile range; NA, not applicable; SABA, short-acting β_2 -agonist.

An empty cell means that the independent variable was not retained in the final multivariable model and the corresponding OR was not available. Values in boldface are statistically significant.

*High-level treatment defined according to GINA as treatment step 4 or 5 (782 subjects were included in the multivariable model).

†Poor symptom control defined by the use of an inhaled short-acting β_2 -agonist at least once a day (827 subjects were included in the multivariable model).

‡Two or more severe exacerbations during the last 12 mo at work; severe exacerbations were defined as those requiring oral corticosteroids for at least 3 consecutive days or emergency room visit or hospitalization^{19,20} (780 subjects were included in the multivariable model).

§Airflow obstruction defined by an FEV₁ <80% predicted value and an FEV₁/FVC ratio of less than <0.70 at the time of the SIC. Multivariable regression analysis for airflow obstruction used the level of treatment and the need for a SABA at the time of the SIC as well as the number of exacerbations during the last 12 mo before the SIC procedure (831 subjects were included in the multivariable model).

¶The level of exposure to the causal agent at work was qualitatively categorized by the investigators as “unchanged/persistent” or “reduced” compared with the conditions of exposure at the time of disease onset.

¶¶The level of activity of the centers was categorized as “high” and “low” on the basis of the median number of positive SICs reported annually (4.1; IQR, 2.5-7.5).

Determinants of severe OA

Few studies have investigated the factors that determine the severity of OA at the time of diagnosis. In a multicenter Italian study of subjects with OA confirmed by SIC, ever smoking was the only factor associated with asthma severity graded according to symptom frequency, activity limitation, and lung function parameters.¹³ A multicenter French study found that only the duration of the symptomatic period before the diagnostic evaluation was a significant predictor of “moderate-persistent” asthma defined by the level of airflow obstruction and nonspecific bronchial hyperresponsiveness.¹⁴

This cohort study is, to our knowledge, the first attempt to comprehensively characterize the determinants of asthma severity in a large cohort of subjects with OA using a multidimensional approach.^{1,19,20} The multivariable analyses confirmed strong interactions between the individual dimensions of asthma severity and control (ie, treatment level, symptom control, severe exacerbations, and airflow obstruction), similar to what has been found in general asthma populations. More specifically, poor symptom control was linked to an increased risk of severe exacerbations^{5,30,31} and severe exacerbations were associated with

greater airflow limitation.^{32,33} In addition, these analyses highlighted differential effects of identified risk factors and the type of causal agent (ie, HMW vs LMW agents) on the individual domains of asthma severity and control, further supporting the importance of capturing separately the diverse dimensions of the disease.^{1,3,19,20}

The results of this study indicated that severe OA while exposed at work, and predominantly its high-intensity treatment component, was associated with “unchanged/persistent” exposure to the causal agent. This relationship was significant although workplace exposure was only qualitatively evaluated by the investigators as being “unchanged/persistent” or “reduced” compared with the conditions that prevailed at the time of the onset of work-related asthma symptoms. Because of the retrospective design of the study, it was not possible to quantify the duration and magnitude of exposure to “reduced” levels of causal agents. A longer duration of work-related asthma symptoms also increased the risk of severe OA, mainly through an impact on the intensity of asthma treatment and the level of airflow obstruction. Although systematic reviews of follow-up studies indicated that subjects with OA related to HMW agents are more likely to

TABLE V. Asthma severity at the time of the SIC in subjects removed from exposure (n = 467) compared with the severity of their asthma while previously exposed at work

Characteristic	At work	Off work (SIC procedure)	P value
GINA treatment step			
Treatment step 0	79 (16.9)	96 (20.6)	.417
Treatment step 1	61 (13.1)	56 (12.0)	
Treatment step 2	24 (5.1)	29 (6.2)	
Treatment step 3	151 (32.3)	154 (33.0)	
Treatment step 4	152 (32.5)	131 (28.1)	
Treatment step 5	0	1 (0.2)	
Frequency of SABA use	332 (71.1)	286 (61.2)	<.001
Never	135 (28.9)	181 (38.8)	<.001
Once or less per week	73 (15.6)	146 (31.3)	
2 or more times a week	110 (23.6)	66 (14.1)	
Once or more a day*	149 (31.9)	74 (15.8)	
≥1 SA exacerbation	124 (26.6)†	22 (4.7)‡	<.001
≥2 SA exacerbations	40 (8.6)†	4 (0.9)‡	<.001
SA§	84 (18.0)	52 (11.1)	.004

SABA, Short-acting β_2 -agonist.

Data are presented as n and % of available data unless otherwise specified. Values in boldface are statistically significant.

*Need for a SABA once or more a day used as a proxy for “poor symptom control.”

†Number of exacerbations during the last 12 mo of exposure at work.

‡Number of exacerbations during the last 12 mo before the SIC procedure.

§Definition of SA adapted from the European Respiratory Society/American Thoracic Society criteria (see [Methods](#)).¹

have a worse outcome after complete avoidance of exposure to the causal agent,^{12,34} the risk of severe OA was not affected by the type of causal agent (ie, LMW vs HMW) in this cross-sectional cohort study that assessed the severity of OA at the time of diagnosis. Nevertheless, when the diverse domains of asthma severity were considered separately, subjects with OA due to LMW agents showed slightly higher rates of severe exacerbations and high-level treatment as compared with OA caused by HMW agents, which is consistent with previous cross-sectional studies.^{35,36} These discordant findings warrant further investigation in longitudinal studies.

In addition, the multivariable logistic regression analyses identified sociodemographic and clinical risk factors for severe OA that have been implicated in SA unrelated to work. The most clinically relevant finding in our cohort was that chronic sputum production was strongly associated with all dimensions of severe OA independently from smoking. These results are consistent with studies in adult patients with asthma that documented significant associations between sputum production and uncontrolled³⁷ or severe^{23,26} asthma.

Despite the low prevalence of childhood asthma in this cohort, it was a strong predictor for severe OA, especially for poor symptom control and—with borderline significance—airflow obstruction. Although atopy is a well-identified risk factor for the development of OA in workers exposed to HMW agents, a history of childhood asthma was not more frequently found in severe OA caused by HMW agents (12.2%) as compared with LMW agents (11.5%). In adult asthma cohorts, the respective effects of the age at asthma onset and its duration on the severity of asthma were often not disentangled. Nevertheless, some investigators reported that an older age at asthma onset had a

greater effect than asthma duration in adult patients with asthma.^{26,38} Interestingly, the analysis of this OA cohort indicated that both a history of childhood asthma and the duration of work-related asthma symptoms had independent effects on asthma severity through different domains.

A low level of education was a significant risk factor for severe OA, mainly through a strong association with poor symptom control. Nonwhite ethnicity was also independently associated with poor symptom control and SA exacerbations, but was not significantly associated with the multicomponent definition of severe OA. These features are likely to reflect a lower socioeconomic status, which can lead to increased risk of SA through various pathways.^{39,40}

This OA cohort revealed several differences compared with the findings of studies conducted in general adult asthma populations. Demographic and clinical risk factors for SA that have been identified in some studies of general asthma populations, namely, female sex,^{41,42} obesity,^{26,42,43} cigarette smoking,^{23,26,44,45} rhinitis,²³ and sinusitis,^{42,43,46–48} did not show an association with severe OA here although chronic sinusitis was associated with high-level treatment ([Table IV](#)). In contrast, no relationship was observed between work-related rhinitis and the severity of OA, which is discordant with the findings of Moscato et al⁴⁹ who reported that moderate-severe occupational rhinitis was associated with more severe OA. However, the severity of rhinitis symptoms was not graded in our study. Of note, obesity showed a borderline significant association with severe OA but only at the time of the SIC procedure in subjects who were no longer exposed to the causal agent. This finding suggests that individual risk factors for SA may become apparent only after avoidance of the causal allergen. In this respect, OA may be regarded as a unique opportunity to investigate the factors that determine the outcome of allergic asthma after avoidance of exposure.

An intriguing observation was the association between dysphonia and severe OA. Dysphonia may result from different mechanisms, including a local adverse effect from the inhalation of high doses of corticosteroids, concomitant “work-associated irritable larynx syndrome” triggered by irritants at work,⁵⁰ or paradoxical vocal cord movement, which is prevalent in patients with asthma with airflow obstruction and may mimic asthma symptoms.⁵¹ It is unlikely that paradoxical vocal cord movement may have led to misclassification of SA in this study because dysphonia was not associated with poor symptom control in multivariable analyses. Although there is increasing awareness of the association between upper/middle airway dysfunction and SA,⁵¹ its clinical relevance warrants further investigation.

Strengths and limitations

The strengths of this study are its large sample size, the homogeneous diagnostic criteria used for identifying OA, and the multidimensional assessment of asthma severity.^{1,3,19,20} However, several limitations deserve thorough discussion. Inherent to the lack of a standardized clinical assessment of workers with suspected OA among participating centers, some potential determinants of SA could not be collected, including nonsteroidal anti-inflammatory drug sensitivity, gastroesophageal reflux disease, psychological disorders, and magnitude of post-bronchodilator FEV₁ reversibility. More importantly, the level of asthma control could not be fully captured^{1,3,19,20} because detailed information about the frequency of daytime/nighttime

symptoms and asthma-related limitation of daily activities was not systematically collected. The retrospective design of the study limited our ability to distinguish severe “refractory” asthma (ie, asthma that remains uncontrolled despite GINA treatment step 4/5) from severe “difficult-to-control” asthma (ie, uncontrolled asthma resulting from poor adherence, poor inhalation technique, or untreated comorbidities despite follow-up by a respiratory specialist for at least 6 months).^{1,3,19,20} In addition, it was not possible to ascertain that the subjects were uniformly treated according to GINA guidelines and that a high-level treatment was necessary to prevent asthma from becoming uncontrolled.¹ The retrospective collection of data pertaining to asthma severity and control may have introduced some bias, especially for subjects who were no longer at work at the time of the diagnostic evaluation.

We acknowledge that this multicenter cohort may not be fully representative of the whole population of workers affected with OA. The proportion of subjects with severe OA might have been overestimated because recruitment from tertiary centers could have introduced a selection bias toward subjects with more severe asthma. Conversely, the prevalence of severe OA might have been underestimated because the assessment of asthma severity was based on spirometry measurements that were available only at baseline of the SIC procedure, at a time where half the subjects had already been removed from exposure. In addition, a potential bias toward inclusion of patients with less severe asthma might have occurred because most centers did not perform SIC in subjects with marked airflow obstruction (see [Appendix E3](#)). However, the broad recruitment from 20 centers throughout Europe is likely to minimize as far as possible the potential selection bias due to local clinical and recruitment practices and to enhance the generalizability of the findings.

CONCLUSIONS

This study shows that the determinants of severe OA include not only potentially modifiable factors (ie “unchanged/persistent” exposure to the causal agent and duration of symptomatic exposure before diagnosis) but also a low sociodemographic status and clinical characteristics (ie, childhood asthma and daily sputum production). Interestingly, data collected in the subset of subjects removed from the causal agent at the time of the diagnostic evaluation suggest that the persistence of SA was predominantly driven by individual risk factors. These results further support the need for an early diagnosis and prompt implementation of environmental interventions to reduce the burden of severe OA. In addition, our findings may help clinicians to identify subjects with OA at high risk for a more severe outcome and contribute to a more personalized management approach aimed at minimizing the health and socioeconomic impacts of the disease.

Acknowledgments

European Network for the Phenotyping of Occupational Asthma (E-PHOCAS) investigators: Olivier Vandenplas and Catherine Riffart (Department of Chest Medicine, Centre Hospitalier Universitaire UCL Namur, Université Catholique de Louvain, Yvoir, Belgium); Pavlina Klusackova (Department of Occupational Medicine, General University Hospital, Charles University, Prague, Czech Republic); David Sherson (Department

of Pulmonary Medicine and Occupational Medicine, Odense University Hospital, Odense, Denmark); Hille Suojalehto and Pirjo Hölttä (Occupational Medicine, Finnish Institute of Occupational Health, Helsinki, Finland); Paula Kauppi (Department of Allergy, Skin and Allergy Hospital, Helsinki University Central Hospital, Helsinki, Finland); Frédéric de Blay and Laura Hurdubaea (Division of Asthma and Allergy, Department of Chest Diseases, University Hospital of Strasbourg, Fédération de Médecine translationnelle, Strasbourg University, Strasbourg, France); Rolf Merget (Institute for Prevention and Occupational Medicine of the German Social Accident Insurance [IPA], Ruhr University, Bochum, Germany); Alexandra M. Preisser and Volker Harth (Institute for Occupational and Maritime Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany); Piero Maestrelli and Paola Mason (Unit of Occupational Medicine and Public Health, University of Padova, Padova, Italy); Gianna Moscato and Patrizia Pignatti (Department of Public Health, Experimental and Forensic Medicine, University of Pavia, and Allergy and Immunology Unit, Istituti Clinici Scientifici Maugeri, IRCCS, Pavia, Italy); Pierluigi Paggiaro and Donatella Talini (Cardio-Thoracic and Vascular Department, University of Pisa, Pisa, Italy); Marco dell’Omo and Ilenia Foletti (Department of Medicine, Section of Occupational Medicine, Respiratory Diseases and Occupational and Environmental Toxicology, University of Perugia, Perugia, Italy); Cecilie Svanes and Jorunn Kirkeleit (Department of Occupational Medicine, Haukeland University Hospital, Bergen, Norway); Jolanta Walusiak-Skorupa and Marta Wiszniewska (Department of Occupational Diseases and Environmental Health, Nofer Institute of Occupational Medicine, Lodz, Poland); Xavier Munoz and Christian Romero-Mesones (Servei Pneumologia, Hospital Vall d’Hebron, Universitat Autònoma de Barcelona and CIBER de Enfermedades Respiratorias [CIBERES], Barcelona, Spain); Joaquin Sastre and Mar Fernandez-Nieto (Department of Allergy, Fundacion Jimenez Diaz and CIBER de Enfermedades Respiratorias [CIBERES], Madrid, Spain); Santiago Quirce and Marta Sanchez-Jareno (Department of Allergy, Hospital La Paz, Institute for Health Research [IdiPAZ] and CIBER de Enfermedades Respiratorias [CIBERES], Madrid, Spain); Paul Cullinan and Julie Cannon (Department of Occupational and Environmental Medicine, Royal Brompton Hospital and Imperial College [NHLI], Royal Brompton and Harefield NHS Foundation Trust, London, UK); Sherwood Burge and Vicky Moore (Occupational Lung Disease Unit, Birmingham Heartlands Hospital, Birmingham, UK); and Jennifer Hoyle (Department of Respiratory Medicine, North Manchester General Hospital, Manchester, UK).

REFERENCES

1. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. *Eur Respir J* 2014;43:343-73.
2. Israel E, Reddel HK. Severe and difficult-to-treat asthma in adults. *N Engl J Med* 2017;377:965-76.
3. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention 2015. Available from: <http://www.ginasthma.org/>. Accessed December 28, 2017.
4. Le Moual N, Siroux V, Pin I, Kauffmann F, Kennedy SM. Asthma severity and exposure to occupational asthmogens. *Am J Respir Crit Care Med* 2005;172:440-5.
5. Le Moual N, Carsin AE, Siroux V, Radon K, Norback D, Toren K, et al. Occupational exposures and uncontrolled adult-onset asthma in the European Community Respiratory Health Survey II. *Eur Respir J* 2014;43:374-86.

6. Tarlo SM, Balmes J, Balkissoon R, Beach J, Beckett W, Bernstein D, et al. Diagnosis and management of work-related asthma: American College Of Chest Physicians Consensus Statement. *Chest* 2008;134:1S-41S.
7. Tarlo SM, Lemiere C. Occupational asthma. *N Engl J Med* 2014;370:640-9.
8. Nicholson P, Cullinan P, Burge P, Boyle C. Occupational asthma: prevention, identification & management: systematic review & recommendations. London: British Occupational Health Research Foundation; 2010.
9. Vandenplas O, Dressel H, Wilken D, Jamart J, Heederik D, Maestrelli P, et al. Management of occupational asthma: cessation or reduction of exposure? A systematic review of available evidence. *Eur Respir J* 2011;38:804-11.
10. de Groene GJ, Pal TM, Beach J, Tarlo SM, Spreuwers D, Frings-Dresen MH, et al. Workplace interventions for treatment of occupational asthma: a Cochrane database of systematic review. *Occup Environ Med* 2012;69:373-4.
11. Vandenplas O, Dressel H, Nowak D, Jamart J. What is the optimal management option for occupational asthma? *Eur Respir Rev* 2012;21:97-104.
12. Maestrelli P, Schlunssen V, Mason P, Sigsgaard T. Contribution of host factors and workplace exposure to the outcome of occupational asthma. *Eur Respir Rev* 2012;21:88-96.
13. Moscato G, Dellabianca A, Maestrelli P, Paggiaro P, Romano C, De Zotti R, et al. Features and severity of occupational asthma upon diagnosis: an Italian multicentric case review. *Allergy* 2002;57:236-42.
14. Descatha A, Leproust H, Choudat D, Garnier R, Paire JC, Ameille J. Factors associated with severity of occupational asthma with a latency period at diagnosis. *Allergy* 2007;62:795-801.
15. Schatz M, Sorkness CA, Li JT, Marcus P, Murray JJ, Nathan RA, et al. Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. *J Allergy Clin Immunol* 2006;117:549-56.
16. Sterk PJ, Fabbri LM, Quanjer PH, Cockcroft DW, O'Byrne PM, Anderson SD, et al. Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. *Eur Respir J Suppl* 1993;16:53-83.
17. Vandenplas O, Suojalehto H, Aasen TB, Baur X, Burge PS, de Blay F, et al. Specific inhalation challenge in the diagnosis of occupational asthma: consensus statement. *Eur Respir J* 2014;43:1573-87.
18. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. *Am J Respir Crit Care Med* 2000;162:2341-51.
19. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. *Am J Respir Crit Care Med* 2009;180:59-99.
20. Bousquet J, Mantzouranis E, Cruz AA, Ait-Khaled N, Baena-Cagnani CE, Bleecker ER, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. *J Allergy Clin Immunol* 2010;126:926-38.
21. Hekking PP, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. *J Allergy Clin Immunol* 2015;135:896-902.
22. von Bulow A, Backer V, Bodtger U, Soes-Petersen NU, Assing KD, Skjold T, et al. The level of diagnostic assessment in severe asthma: a nationwide real-life study. *Respir Med* 2017;124:21-9.
23. Cazzoletti L, Marcon A, Corsico A, Janson C, Jarvis D, Pin I, et al. Asthma severity according to Global Initiative for Asthma and its determinants: an international study. *Int Arch Allergy Immunol* 2010;151:70-9.
24. von Bulow A, Kriegbaum M, Backer V, Porsbjerg C. The prevalence of severe asthma and low asthma control among Danish adults. *J Allergy Clin Immunol Pract* 2014;2:759-67.
25. Zeiger RS, Schatz M, Dalal AA, Qian L, Chen W, Ngor EW, et al. Utilization and costs of severe uncontrolled asthma in a managed-care setting. *J Allergy Clin Immunol Pract* 2016;4:120-129.e3.
26. Mincheva R, Ekerljung L, Bossios A, Lundback B, Lotvall J. High prevalence of severe asthma in a large random population study. *J Allergy Clin Immunol* 2018;141:2256-2264.e2.
27. Lemiere C, Forget A, Dufour MH, Boulet LP, Blais L. Characteristics and medical resource use of asthmatic subjects with and without work-related asthma. *J Allergy Clin Immunol* 2007;120:1354-9.
28. Lemiere C, Boulet LP, Chabaille S, Forget A, Chirys S, Villeneuve H, et al. Work-exacerbated asthma and occupational asthma: do they really differ? *J Allergy Clin Immunol* 2013;131:704-10.
29. Malo JL. Asthma may be more severe if it is work-related. *Am J Respir Crit Care Med* 2005;172:406-7.
30. Haselkorn T, Fish JE, Zeiger RS, Szefer SJ, Miller DP, Chipps BE, et al. Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. *J Allergy Clin Immunol* 2009;124:895-902.e1-4.
31. Calhoun WJ, Haselkorn T, Mink DR, Miller DP, Dorenbaum A, Zeiger RS. Clinical burden and predictors of asthma exacerbations in patients on guideline-based steps 4-6 asthma therapy in the TENOR cohort. *J Allergy Clin Immunol Pract* 2014;2:193-200.
32. Kupczyk M, ten Brinke A, Sterk PJ, Bel EH, Papi A, Chanez P, et al. Frequent exacerbations—a distinct phenotype of severe asthma. *Clin Exp Allergy* 2014;44:212-21.
33. Matsunaga K, Hirano T, Oka A, Tanaka A, Kanai K, Kikuchi T, et al. Progression of irreversible airflow limitation in asthma: correlation with severe exacerbations. *J Allergy Clin Immunol Pract* 2015;3:759-764.e1.
34. Rachiotis G, Savani R, Brant A, MacNeill SJ, Newman Taylor A, Cullinan P. Outcome of occupational asthma after cessation of exposure: a systematic review. *Thorax* 2007;62:147-52.
35. Meca O, Cruz MJ, Sanchez-Ortiz M, Gonzalez-Barcala FJ, Ojanguren I, Munoz X. Do low molecular weight agents cause more severe asthma than high molecular weight agents? *PLoS One* 2016;11:e0156141.
36. Vandenplas O, Godet J, Hurdubaea L, Riffart C, Suojalehto H, Wiszniewska M, et al, on behalf of the European network for the Phenotyping of Occupational Asthma (E-PHOCAS). Are high- and low-molecular-weight sensitizing agents associated with different clinical phenotypes of occupational asthma? *Allergy* 2019;74:261-72.
37. Siroux V, Boudier A, Bousquet J, Bresson JL, Cracowski JL, Ferran J, et al. Phenotypic determinants of uncontrolled asthma. *J Allergy Clin Immunol* 2009;124:681-687.e3.
38. Zein JG, Dweik RA, Comhair SA, Bleecker ER, Moore WC, Peters SP, et al. Asthma is more severe in older adults. *PLoS One* 2015;10:e0133490.
39. Roberts SE, Button LA, Hopkin JM, Goldacre MJ, Lyons RA, Rodgers SE, et al. Influence of social deprivation and air pollutants on serious asthma. *Eur Respir J* 2012;40:785-8.
40. Trupin L, Katz PP, Balmes JR, Chen H, Yelin EH, Omachi T, et al. Mediators of the socioeconomic gradient in outcomes of adult asthma and rhinitis. *Am J Public Health* 2013;103:e31-8.
41. Teague WG, Phillips BR, Fahy JV, Wenzel SE, Fitzpatrick AM, Moore WC, et al. Baseline features of the Severe Asthma Research Program (SARP III) cohort: differences with age. *J Allergy Clin Immunol Pract* 2018;6:545-554.e4.
42. Westerhof GA, Coumou H, de Nijs SB, Weersink EJ, Bel EH. Clinical predictors of remission and persistence of adult-onset asthma. *J Allergy Clin Immunol* 2018;141:104-109.e3.
43. Hinks TS, Brown T, Lau LC, Rupani H, Barber C, Elliott S, et al. Multidimensional endotyping in patients with severe asthma reveals inflammatory heterogeneity in matrix metalloproteinases and chitinase 3-like protein 1. *J Allergy Clin Immunol* 2016;138:61-75.
44. Thomson NC, Chaudhuri R, Heaney LG, Bucknall C, Niven RM, Brightling CE, et al. Clinical outcomes and inflammatory biomarkers in current smokers and ex-smokers with severe asthma. *J Allergy Clin Immunol* 2013;131:1008-16.
45. Westerhof GA, Vollema EM, Weersink EJ, Reinartz SM, de Nijs SB, Bel EH. Predictors for the development of progressive severity in new-onset adult asthma. *J Allergy Clin Immunol* 2014;134:1051-1056.e2.
46. ten Brinke A, Sterk PJ, Masclee AA, Spinoven P, Schmidt JT, Zwinderman AH, et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. *Eur Respir J* 2005;26:812-8.
47. Moore WC, Bleecker ER, Curran-Everett D, Erzurum SC, Ameredes BT, Bacharier L, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. *J Allergy Clin Immunol* 2007;119:405-13.
48. Amelink M, de Groot JC, de Nijs SB, Lutter R, Zwinderman AH, Sterk PJ, et al. Severe adult-onset asthma: a distinct phenotype. *J Allergy Clin Immunol* 2013;132:336-41.
49. Moscato G, Pala G, Folletti I, Siracusa A, Quirce S. Occupational rhinitis affects occupational asthma severity. *J Occup Health* 2016;58:310-3.
50. Hoy RF, Ribeiro M, Anderson J, Tarlo SM. Work-associated irritable larynx syndrome. *Occup Med (Lond)* 2010;60:546-51.
51. Low K, Ruane L, Uddin N, Finlay P, Lau KK, Hamza K, et al. Abnormal vocal cord movement in patients with and without airway obstruction and asthma symptoms. *Clin Exp Allergy* 2017;47:200-7.

ONLINE REPOSITORY

APPENDIX E1

Cohort recruitment

Twenty-four European tertiary centers performing SICs for the diagnosis of OA^{E1} were invited to participate to this retrospective cohort, of which 20 agreed to complete the standardized database. Patient eligibility for inclusion in this cohort was based on a diagnosis of OA objectively confirmed by a positive SIC result.

Nine centers reported over the full 10-year study period, whereas 11 centers included patients with a positive SIC result over periods ranging from 3 to 9 years according to available data. The median annual number of positive SIC results per center was 4.1 (interquartile range, 2.5-7.5).

For each subject entered in the database, investigators were asked to provide the maximum fall in FEV₁ expressed as percent from baseline value that was recorded after the end of the challenge exposure as well as the level of nonspecific bronchial hyperresponsiveness (NSBH) measured before the SIC and 24 hours after the end of challenge exposure (see below “Assessment of NSBH”). A positive SIC result was defined by either a greater than or equal to 15% fall in FEV₁ at any time point during the postchallenge monitoring period or a significant increase in the postchallenge level of NSBH as compared with the baseline value.^{E2-E4}

One thousand one hundred eighty of the 1249 reported subjects had either a documented greater than or equal to 15% fall in FEV₁ during SIC (n = 1105) or a significant increase in the postchallenge level of NSBH in the absence of a greater than or equal to 15% fall in FEV₁ (n = 75). Of these 1180 eligible subjects, 183 were excluded from analysis because of incomplete information on asthma medications (n = 89), asthma exacerbations (n = 97), and/or baseline spirometry (n = 5), which were considered key variables for this analysis. The final cohort included 997 analyzable subjects.

Data collection

Detailed information on demographic, clinical, occupational, and physiological characteristics of the subjects at the time of the diagnostic evaluation was entered in a standardized Excel database in each participating center by local investigators (see Appendix E1). The requested information was exclusively retrieved from medical charts in 10 centers, whereas in the other centers, all or part of the data had been prospectively entered in existing local databases. The standardized databases were then checked by 3 investigators (O.V., C.R., and J.D.), pooled together, and centralized at the Strasbourg University (F.d.B., N.M., and J.G.).

APPENDIX E2

Assessment of NSBH

The database collected information on the level of NSBH measured at baseline and 24 hours after the end of challenge exposure. The level of NSBH was expressed as the concentration or dose of the pharmacological agent inducing a 15% or 20% fall in FEV₁ (PC/PD_{15%-20%}) according to the bronchoprovocation method used in each center. Because participating centers used 6 different methods, the level of NSBH was only categorized as “absence of NSBH,” “mild NSBH,” and

“moderate-to-severe NSBH” on the basis of available recommendations^{E5-E7} or using a consensus Delphi approach among investigators. The bronchoprovocation methods and threshold values used for defining the level of NSBH are detailed in Table E2. Overall, NSBH was not assessed in 82 of 997 subjects. Among these subjects, the diagnosis of asthma was documented by reversible airflow obstruction on spirometry (n = 37) or daily variations in peak expiratory flow (n = 30). The diagnosis of asthma was not formally documented in 15 subjects. A significant increase in postchallenge level of NSBH was defined as a greater than or equal to 2-fold decrease in the PC/PD_{15%-20%} value recorded 24 hours after the challenge exposure as compared with the baseline value (ie, a pre-/post-PC/PD_{15%-20%} ratio ≥ 2).^{E2-E4}

APPENDIX E3

Methodology of specific inhalation challenges

Participating investigators completed a questionnaire to evaluate whether (1) a control (placebo) test was performed before challenging the subjects with the suspected occupational agent(s) and (2) a functional monitoring of at least 6 hours after the end of challenge exposures was completed to ensure compliance with international recommendations.^{E4,E5} They were also requested to state which lower limit value of FEV₁ they considered a contraindication for performing an SIC procedure. This lower limit of FEV₁ was 70% of predicted value in 11 centers, 65% in 1 center, 60% in 5 centers, and 50% in 2 centers.

Asthma medications were adapted according to the Global Initiative for Asthma guidelines in subjects who showed increased variability in FEV₁ or peak expiratory flow rates before the SIC procedure or during the control day. Long-acting and short-acting bronchodilators were stopped before the SIC procedure according to their duration of action. Inhaled corticosteroids were withdrawn for 2 to 7 days before the SIC procedure in 18 centers and for longer periods (ie, at least 15 days or 28 days) in 2 centers. However, the daily dose of inhaled corticosteroids could be administered as a single evening dose during the SIC procedure in subjects whose asthma became unstable after withdrawal of inhaled corticosteroids.

For each SIC, the database requested information on the method used for delivering the suspected occupational agent either through a “realistic” approach mimicking the workplace exposure (n = 944)^{E8} or the inhalation of an “allergen extract” (n = 53). A detailed description of the methods used for delivering various occupational agents during SICs has been compiled by the European Taskforce on SIC from 12 specialist centers participating in the current cohort study.^{E4} This “Handbook of procedures for specific inhalation challenge testing in the diagnosis of occupational asthma” is available from www.erj.ersjournals.com as an online supplementary material to the European Respiratory Society consensus statement on SIC in the diagnosis of OA.^{E4}

The database collected the maximum fall in FEV₁ expressed as percent from baseline value that was recorded during 2 distinct time periods of the postchallenge functional monitoring: (1) the period between the end of the challenge exposure and the 60th minute postexposure (ie, the “early component” of the bronchial response) and (2) the period between the 60th minute postchallenge and the end of the post-SIC follow-up (ie, the “late component” of the bronchial response).

The results of the SICs were interpreted *a posteriori* according to standardized criteria.^{E4} A positive SIC result was defined by either a greater than or equal to 15% fall in FEV₁ at any time during the postchallenge monitoring or a 2-fold or greater increase in the postchallenge level of NSBH in the absence of significant changes in FEV. Among the 997 subjects included in this analysis, 935 subjects showed a greater than or equal to 15% fall in FEV₁ during SIC and 62 a significant increase in the postchallenge level of NSBH.

APPENDIX E4

Statistical analysis

Multivariable logistic regression analysis was carried out using a binomial generalized linear model to identify the clinical and physiological characteristics that were significantly and independently associated with severe OA. The potential explanatory variables incorporated into these regressions were selected on the basis of bivariate exploratory analyses and potential risk factors for SA identified in the literature. The model consisted of the following variables: age (>42 years vs ≤42 years); sex; ethnicity (white vs nonwhite); body mass index (≥30 kg/m² vs <30 kg/m²); atopy (presence vs absence of a positive SPT response to at least 1 common aeroallergen); smoking status (never vs ever being a smoker); level of education (≤6 years vs >6 years); age at asthma onset (<12 years vs ≥12 years); type of causal agent (LMW vs HMW agent); duration of asthma symptoms at work; level of exposure during the last month at work (persistently high vs reduced); work-related rhinitis or conjunctivitis (yes vs no); daily sputum production (yes vs no); chronic sinusitis (yes vs no); dysphonia at work (yes vs no); and recruitment from a center with a “high activity” (ie, >4 positive SICs per year) versus a “low activity”

(ie, ≤4 positive SICs per year). The various components of asthma severity (ie, high-intensity treatment; poor symptom control; ≥2 severe exacerbations during the last 12 months at work; and airflow obstruction) were not included in this analysis because they are part of the definition of SA. Model selection was performed on this data set with removed missing values using a stepwise algorithm (both forward and backward stepwise searches) based on Akaike information criterion (stepAIC function in the MASS package). This procedure selects the most parsimonious model with informative variables. OR (and CI) are reported for each variable retained in the final model. Missing values were not imputed.

Additional multivariable logistic regressions were conducted to identify the variables associated with each of the domains used to define SA while at work: high-intensity treatment (ie, GINA treatment step 4 or 5); poor symptom control (ie, short-acting β-agonist ≥1/d); 2 or more severe exacerbations during the last 12 months at work; and airflow obstruction. The same independent variables as those used in the multivariable analysis of severe OA were included in these logistic regressions and the best models were selected on the basis of Akaike information criterion. The severity domains were also included as independent variables in the models where appropriate, but airway obstruction was not included because spirometric values were those measured at the time of the SIC procedure when 46.8% of the study subjects were already removed from exposure. Likewise, the level of treatment and the need for a short-acting β-agonist at the time of the SIC procedure, and the number of exacerbations during the last 12 months before the SIC procedure were used in the multivariable regression analysis of airway obstruction to take into account the potential effect of cessation of exposure in a substantial fraction of the subjects.

TABLE E1. Methods used for measuring the level of NSBH

Method (pharmacological agent)	No. of centers (subjects)	Threshold values for nonspecific bronchial hyperresponsiveness		
		Moderate-to-severe	Mild	Absent
Tidal breath method (histamine/methacholine) ^{E5,E6}	5 (404)	PC ₂₀ < 1 mg/mL	PC ₂₀ : 1-16 mg/mL	PC ₂₀ > 16 mg/mL
Five-breath dosimeter method (methacholine) ^{E5,E6}	9 (257)	PD ₂₀ < 0.1 mg	PD ₂₀ : 0.1-1.5 mg	PD ₂₀ > 1.5 mg
Rapid dosimeter method (histamine) ^{E7}	2 (185)	PC ₂₀ < 1 mg/mL	PC ₂₀ : 1-16 mg/mL	PC ₂₀ > 16 mg/mL
		PD ₁₅ < 0.4 mg	PD ₁₅ : 0.4-1.6 mg	PD ₁₅ > 1.6 mg
APS dosimeter method (histamine/methacholine) ^{E9}	2 (66)	PD ₂₀ < 0.1 mg	PD ₂₀ : 0.1-1.4 mg	PD ₂₀ < 1.4 mg
Reservoir bag dosimeter method (methacholine) ^{E10}	1 (2)	PC ₂₀ < 1 mg/mL	PC ₂₀ : 1-16 mg/mL	PC ₂₀ > 16 mg/mL
		PD ₂₀ or PD ₁₀₀ sRt < 0.1 mg	PD ₂₀ or PD ₁₀₀ sRt: 0.1-0.3 mg	PD ₂₀ or PD ₁₀₀ sRt > 0.3 mg
Dosimeter method (mannitol) ^{E11}	1 (1)	PD ₁₅ ≤ 250 mg	PD ₁₅ : 251-635 mg	PD ₁₅ > 635 mg

PC/PD_{15/20}, Provocative concentration of pharmacological agent inducing a 15% or 20% fall in FEV₁; PD₁₀₀ sRt, provocative concentration of pharmacological agent inducing a doubling of specific airway resistance.

TABLE E2. Causal agents

HMW agents	n (%) [*]	LMW agents	n (%) [*]
Flour/grains	341 (34.6)	Isocyanates	139 (14.1)
Latex	35 (3.6)	Persulfate salts	57 (5.8)
Enzymes	23 (2.3)	Quaternary ammonium compounds	38 (3.9)
Storage mites	10 (1.0)	Metals	30 (3.0)
Cow dander	9 (0.9)	Welding	30 (3.0)
Rodents	9 (0.9)	Wood dusts	28 (2.8)
Fish/seafood	8 (0.8)	Acrylate compounds	28 (2.8)
Ornamental plants	6 (0.6)	Cleaning products/disinfectant (NOS)	26 (2.6)
Insects and derived products	5 (0.5)	Aldehydes	15 (1.5)
Vegetal gums	3 (0.3)	Metal working fluids	15 (1.5)
Soybean flour	3 (0.3)	Resins/glues/paints (NOS)	15 (1.5)
Spices	3 (0.3)	Epoxy resins	14 (1.4)
Molds	2 (0.2)	Amines	10 (1.0)
Various plant-derived products	22 (2.2)	Acid anhydrides	10 (1.0)
Various animals and derived products	14 (1.4)	Drugs	9 (0.9)
		Colophony	4 (0.4)
		Reactive dyes	2 (0.2)
		Styrene	2 (0.2)
		Triglycidylisocyanurate	1 (0.1)
		Various LMW agents	17 (1.7)
Total	493 (50.1)	Total	492 (49.9)

NOS, Not otherwise specified.

^{*}% of total identified agents (n = 985); the causal agent was not precisely identified in 12 subjects.

REFERENCES

- E1. Suojalehto H, Cullinan P, European Respiratory Society Task Force on Specific Inhalation Challenges with Occupational Asthma. Specific inhalation challenge tests for occupational asthma in Europe: a survey. *Eur Respir Rev* 2014;23:266-70.
- E2. Vandenplas O, Delwiche JP, Jamart J, Van de Weyer R. Increase in non-specific bronchial hyperresponsiveness as an early marker of bronchial response to occupational agents during specific inhalation challenges. *Thorax* 1996;51:472-8.
- E3. Sastre J, Fernandez-Nieto M, Novalbos A, De Las Heras M, Cuesta J, Quirce S. Need for monitoring nonspecific bronchial hyperresponsiveness before and after isocyanate inhalation challenge. *Chest* 2003;123:1276-9.
- E4. Vandenplas O, Suojalehto H, Aasen TB, Baur X, Burge PS, de Blay F, et al. Specific inhalation challenge in the diagnosis of occupational asthma: consensus statement. *Eur Respir J* 2014;43:1573-87.
- E5. Sterk PJ, Fabbri LM, Quanjer PH, Cockcroft DW, O'Byrne PM, Anderson SD, et al. Airway responsiveness: standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. *Eur Respir J Suppl* 1993;16:53-83.
- E6. Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. *Am J Respir Crit Care Med* 2000;161:309-29.
- E7. Sovijarvi AR, Malmberg LP, Reinikainen K, Ryttilä P, Poppius H. A rapid dosimetric method with controlled tidal breathing for histamine challenge: repeatability and distribution of bronchial reactivity in a clinical material. *Chest* 1993;104:164-70.
- E8. Pepys J, Hutchcroft BJ. Bronchial provocation tests in etiologic diagnosis and analysis of asthma. *Am Rev Respir Dis* 1975;112:829-59.
- E9. Schulze J, Rosewich M, Riemer C, Dressler M, Rose MA, Zielen S. Methacholine challenge—comparison of an ATS protocol to a new rapid single concentration technique. *Respir Med* 2009;103:1898-903.
- E10. Merget R, Schultze-Werninghaus G, Bode F, Bergmann EM, Zachgo W, Meier-Sydow J. Quantitative skin prick and bronchial provocation tests with platinum salt. *Br J Ind Med* 1991;48:830-7.
- E11. Anderson SD, Brannan J, Spring J, Spalding N, Rodwell LT, Chan K, et al. A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol. *Am J Respir Crit Care Med* 1997;156:758-65.

Reproduced with permission of copyright owner. Further reproduction prohibited without permission.